NewAmsterdam Pharma announces upcoming presentations at the European Society of Cardiology (ESC) Congress 2026. NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib development program at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 - 31, 2026 in Munich, Germany. Presentation details are as follows: Title: Determinants of Short Term Lp(a) Variability in Phase 3 Obicetrapib Trials Session Title: Novel Lipid Lowering Therapies for Residual Risk Session Number: 3579 Moderated Poster Presentation Date and Time: Friday, August 28, 2026 at 10:15-11:00 CET Location: Station 2, Research Gallery Hall A1 Presenters: John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer, NewAmsterdam Pharma Title: Pooled On-Treatment Lipid-Lowering Efficacy of the CETP Inhibitor Obicetrapib in Phase III Trials Session Title: Lipid Lowering and Cardiovascular Outcomes Session Number: 3582 Moderated Poster Presentation Date and Time: Sunday, August 30, 2026 at 10:15-11:00 CET Location: Station 2, Research Gallery Hall A1 Presenter: Mathijs A.C. de Kleer Title: Extreme HDL-C Associated Increased Mortality is Explained by Confounding Due to Progressively Increasing Alcohol-Induced Multisystem Morbidity Session Title: Lipids and Myocardial Infarction Session Number: 3102 Oral Presentation Date and Time: Monday, August 31, 2026 at 12:30-12:40 CET Location: Science Box 5, Research Gateway Hall A1 Presenter: Brian A. Ference, M.D., MPhil, FACC, FESC About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. NewAmsterdam Pharma Company seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Media Contact Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 [email protected] Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected]

NewAmsterdam Pharma reported second quarter 2026 financial results and announced positive regulatory progress for obicetrapib, its cholesterol-lowering drug candidate. The European Medicines Agency's CHMP has recommended marketing authorisation for obicetrapib as both a monotherapy and in combination with ezetimibe for treating hypercholesterolemia and mixed dyslipidemia. A final European Commission decision is expected later this year. The company holds $678.3 million in cash, cash equivalents and marketable securities as of 30 June 2026, down from $728.9 million at year-end 2025. Second quarter net loss was $64.1 million compared to $17.4 million in the same period last year. NewAmsterdam plans an interim analysis of its PREVAIL cardiovascular outcomes trial in fourth quarter 2026, with results expected in first quarter 2027. Topline data from the RUBENS Phase 3 trial is anticipated by year-end 2026.

NewAmsterdam Pharma to host Investor Day on August 5, 2026. NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an Investor Day event for analysts and investors on August 5, 2026 beginning at 9:00 a.m. ET in New York City. Please join members of its management team, including: Michael Davidson, M.D., Chief Executive Officer; John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer; BJ Jones, Chief Commercial Officer; Ian Somaiya, Chief Financial Officer; and Matthew Philippe, Executive Vice President and Head of Investor Relations. A live webcast of the Investor Day event will be available, and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at ir.newamsterdampharma.com at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. NewAmsterdam Pharma Company seek to fill a significant unmet need for a safe, well-tolerated and convenient therapy that lowers LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Media Contact Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 [email protected] Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected]